Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

PI3Kδ Inhibitor Parsaclisib in Combination With Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in Participants With Previously Untreated Peripheral T-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05238064
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:47.871312+00:00
Published At
2022-02-14T00:00:00+00:00
Record Updated At
2022-02-14
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["PI3K\u03b4 Inhibitor", "Parsaclisib", "CHOP", "PTCL"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-02-14"
protocolSection.identificationModule.nctId
"NCT05238064"
protocolSection.identificationModule.officialTitle
"PI3K\u03b4 Inhibitor Parsaclisib in Combination With Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in Participants With Previously Untreated Peripheral T-cell Lymphoma"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • PI3Kδ Inhibitor (protocolSection.conditionsModule.conditions)
  • Parsaclisib (protocolSection.conditionsModule.conditions)
  • CHOP (protocolSection.conditionsModule.conditions)
  • PTCL (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.